Levofloxacin in patients with severe respiratory tract infection.
Odagiri
S
S
Department of Respiratory Diseases, Kanagawa Prefectural Cardiovascular and Respiratory Diseases Center, Yokohama, Japan.
D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001249:Asthma / Q000150:complications; D001991:Bronchitis / Q000188:drug therapy / Q000382:microbiology; D002908:Chronic Disease; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D006801:Humans; D064704:Levofloxacin; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D015242:Ofloxacin / Q000627:therapeutic use*; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D064704:Levofloxacin; D015242:Ofloxacin; D017291:Clarithromycin